{"id":16877,"date":"2024-09-29T09:46:59","date_gmt":"2024-09-29T07:46:59","guid":{"rendered":"https:\/\/inmuno.es\/?page_id=16877"},"modified":"2024-09-29T09:48:41","modified_gmt":"2024-09-29T07:48:41","slug":"journal-of-leukocyte-biology","status":"publish","type":"page","link":"https:\/\/inmuno.es\/index.php\/journal-of-leukocyte-biology\/","title":{"rendered":"Journal of Leukocyte Biology"},"content":{"rendered":"<ul class=\"wp-block-latest-posts__list is-grid has-dates has-author wp-block-latest-posts is-layout-flow wp-block-latest-posts-is-layout-flow\"><li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/24\/prostaglandin-d2-production-in-obese-mice-is-associated-with-reduced-lung-inflammation-and-improved-control-of-francisella-tularensis-and-bordetella-pertussis-infection\/\">Prostaglandin D2 production in obese mice is associated with reduced lung inflammation and improved control of Francisella tularensis and Bordetella pertussis infection<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-09-24T06:46:04+02:00\" class=\"wp-block-latest-posts__post-date\">24 de September de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Immunol. 2026 Aug 29;215(9):vkag254. doi: 10.1093\/jimmun\/vkag254. ABSTRACT Obesity is a risk factor for severe respiratory viral infections, but its impact on bacterial respiratory diseases remains unclear and is sometimes paradoxical. Herein, we demonstrate that diet-induced obese, male C57BL\/6J mice exhibited increased resistance to pulmonary infection with Francisella tularensis and Bordetella pertussis compared with lean &#8230; <a title=\"Prostaglandin D2 production in obese mice is associated with reduced lung inflammation and improved control of Francisella tularensis and Bordetella pertussis infection\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/24\/prostaglandin-d2-production-in-obese-mice-is-associated-with-reduced-lung-inflammation-and-improved-control-of-francisella-tularensis-and-bordetella-pertussis-infection\/\" aria-label=\"Read more about Prostaglandin D2 production in obese mice is associated with reduced lung inflammation and improved control of Francisella tularensis and Bordetella pertussis infection\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1916491\">Dissecting the mechanism of action of the adjuvant system AS01 in human immune cells: synergy of QS-21 and monophosphoryl lipid A and role of type I interferons<\/a><div class=\"wp-block-latest-posts__post-author\">by Michelle Poe<\/div><time datetime=\"2026-09-24T02:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">24 de September de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">The adjuvant system AS01 comprised of the TLR4 agonist monophosphoryl lipid A (MPLA) and the saponin QS-21 embedded in liposomes is currently used in recombinant vaccines against shingles, respiratory syncytial virus infection, and malaria. The efficac&#8230;<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1971227\">Maternal rubella immunity gaps in the vaccine era: a seroepidemiological study of pregnant women in Jiangsu, China<\/a><div class=\"wp-block-latest-posts__post-author\">by Xiang Sun<\/div><time datetime=\"2026-09-24T02:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">24 de September de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">BackgroundRubella elimination has substantially reduced virus circulation in China, but the changing pattern of immunity among women entering reproductive age remains unclear. We assessed the contemporary rubella immunity profile among pregnant women i&#8230;<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1930311\">Transient short-chain fatty acid exposure and the temporal question of epithelial barrier immunity<\/a><div class=\"wp-block-latest-posts__post-author\">by Rebecca Lewandowski<\/div><time datetime=\"2026-09-24T02:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">24 de September de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Studies of microbiome-targeted interventions often use persistence of an administered organism or endpoint metabolite abundance as markers of biological consequence, but host barriers may be altered by microbial chemistry after the initiating exposure &#8230;<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1956075\">Real-world outcomes of atezolizumab\u2013bevacizumab and durvalumab\u2013tremelimumab in unresectable hepatocellular carcinoma: a systematic review with covariate-adjusted meta-regression and exploratory machine learning analysis<\/a><div class=\"wp-block-latest-posts__post-author\">by Jongin Lee<\/div><time datetime=\"2026-09-24T02:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">24 de September de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Background\/purposeAtezolizumab\u2013bevacizumab (AB) and durvalumab\u2013tremelimumab (DT) are standard first-line therapies for unresectable hepatocellular carcinoma (uHCC), but their comparative effectiveness remains uncertain.MethodsWe included 76 observation&#8230;<\/div><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":16879,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-16877","page","type-page","status-publish","has-post-thumbnail"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=16877"}],"version-history":[{"count":1,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16877\/revisions"}],"predecessor-version":[{"id":16878,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16877\/revisions\/16878"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media\/16879"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=16877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}